Your browser is outdated!

To ensure you have the best experience and security possible, update your browser. Update now


Akram Youssef

Commercial - Strategic Planning - Marketing - Market Access - Business Development

Akram Youssef
41 years old
United States (New Jersey)
Professional Status
Open to opportunities
About Me
Accomplished global executive led and developed a range of diverse and complex pharma sector businesses with proven sales, marketing, market access, commercial operations, strategic planning, portfolio strategy and business development track record of success on both inline and pipeline assets for large, complex organizations globally.
Courageous and decisive P&L business leader with proven track record of achieving aspirational organizational objectives having profitably turned around an under-performing businesses exceeding goals consistently.
Influential business leader having led and contributed to executive committees, strategic initiatives and global programs shaping and driving strategy for multinational organizations.
Insightful strategist and change agent having overcome resistance and gained buy-in to successfully execute key strategic initiatives.
Passionate customer advocate skilled at balancing both internal and external priorities having eliminated barriers to access in various markets around the globe.
Strategic partner skilled at influencing and collaborating with global, region and local networks across a complex, matrix structure capable of establishing sponsorship and consensus under highly resistant and challenging conditions.
Authentic leader with a proven track record of building, investing in and empowering teams.
  • Led RE search and evaluate project to identify either compound or a company acquisition opportunities
  • Supported global BD&L early projects
  • Created and Executed the market access framework establishing Novartis Vaccines presence in various markets across Europe
  • Led cross functional teams of finance, legal, supply chain, manufacturing and packaging to support Novartis Vaccines geographic expansion initiatives
  • Owned financials outlook planning including P&L, Cash Flows, EBIT and NPV
  • Led processes' improvement initiatives starting with strategic processes of business planning, forecasting and launch planning also extended to operational aspects of incoterms, payment terms, Forex management, multi-language packaging and label implications in various markets
  • Launched 2 major oncology brands (Avastin and Tarceva) during 2006-2007
  • Launched 1 major anemia brand (Mircera) during 2008-2009
  • Launched 1 major vaccine brand (Menveo) during 2009-2010
  • Launched Herceptin in Adjuvant Breast Cancer locally in Egypt in 2006
  • Launched new indications as part of product life cycle management (Herceptin in Adjuvant Breast Cancer)
  • Led a major work stream within the global pre-launch project team for IL-6 Inhibitor (Actemra)
  • Led the preparation and submission of pricing and reimbursement dossiers of various vaccine brands in many European markets
  • Led the introduction of 3 major Oncology brands to the MoH formulary and Health Insurance List tripling their sales in 2 years
  • Managed external stakeholders' relations with key private insurances and funding bodies creating leverage/synergy interactions
  • Managed the adaptation of health economics, cost effectiveness and budget impact models for local use in various markets across Middle East, North Africa and Europe
  • Planned and executed "Breast Cancer Awareness Campaign" locally in Egypt in 2007 endorsed by the first lady and led to around 1 mio women received the mamogram
  • Contributed to the "Middle East Breast Cancer Awareness Campaign" in 2006
  • Contributed to the local adaptation and execution of globally led awareness campaigns for Breast Cancer, Lung Cancer and Colorectal Cancer
  • Has been working with KoLs in oncology, rheumatology, anemia and vaccines for the past 10 years
  • Successfully built Roche and Novartis advisory boards in those disease areas and aligned them for productive outcomes including better market understanding, high impact strategic approaches, influential lobbying for driving pricing and reimbursement
  • Managed KoL profiling, segmentation and resources allocation
  • Identified and developed new KoLs through perceptorship programs, speakers' trainings and media trainings
  • Established NVD external and internal distribution network in various markets across Europe
  • Managed co-joint forecast, shortage risk assessment, expiry risk optimization and suppliers' development programs
  • Led distributors' involvement in pre-launch and launch planning and implementation